Tiffany Spaulding, DO
Family Medicine · Casper, WYNPI 1679704753
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 151 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 21.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $563 and has fallen 77.4% since, to $127 in 2024. Among family medicine clinicians in WY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 151 payments — averaging $16.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$534
- Johnson & Johnson$243
- Amgen$194
- Astellas Pharma US Inc$144
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$134
- AstraZeneca$132
- plus $1K from 23 others
What the payments were for
- Food & beverage$2,466100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 26 | $534 |
| Johnson & Johnson | 17 | $243 |
| Amgen(2 entities) | 11 | $194 |
| Astellas Pharma US Inc | 7 | $144 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $134 |
| AstraZeneca | 9 | $132 |
| Otsuka America Pharmaceutical, Inc. | 6 | $128 |
| Lilly USA, LLC | 9 | $113 |
| GSK | 8 | $111 |
| Sanofi-aventis U.S. LLC | 7 | $107 |
| Teva Pharmaceuticals USA, Inc. | 6 | $94 |
| Pfizer | 5 | $71 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $54 |
| Novo Nordisk | 3 | $51 |
| Axsome Therapeutics, Inc. | 2 | $41 |
| Boston Scientific | 3 | $41 |
| Genentech USA, Inc. | 3 | $39 |
| Amarin Pharma, Inc. | 2 | $33 |
| Bayer | 2 | $28 |
| Boehringer Ingelheim | 2 | $26 |
| UCB, Inc. | 1 | $23 |
| Biogen | 1 | $19 |
| Hologic Sales And Service, LLC | 1 | $18 |
| Merz North America, Inc. | 1 | $18 |
| Edwards Lifesciences | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Mayne Pharma Commercial LLC | 1 | $14 |
| Novartis | 1 | $13 |
| Neurelis, Inc. | 1 | $13 |
How this compares
$2,466 in reported general payments places this provider in the 90th percentile of 237 family medicine providers in Wyoming.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 24 | $14,566 |
| MyrbetriqMirabegron | 11 | $7,798 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $4,463 |
| Levothyroxine Sodium | 55 | $621 |
| Np ThyroidThyroid,pork | 14 | $537 |
| Potassium Chloride | 23 | $528 |
| Omeprazole | 31 | $256 |
| Liothyronine Sodium | 13 | $222 |
| Atorvastatin Calcium | 33 | $214 |
| Simvastatin | 36 | $213 |
| Ketoconazole | 11 | $212 |
| Escitalopram Oxalate | 23 | $202 |
| Estradiol | 11 | $192 |
| Pantoprazole Sodium | 12 | $179 |
| Tamsulosin Hcl | 16 | $168 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $132 | $14,56624 claims |
| Astellas Pharma US IncMyrbetriq | $144 | $7,79811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 237 family medicine providers in Wyoming.
Other family medicine in Casper
- Joseph SchoeberCasper$176K
- James McLennanCasper$13K
- Karlynn SieversCasper$10K
- Eric LawrenceCasper$7K
- Louis RoussalisCasper$5K
- Joseph MickelsonCasper$5K
- Jonathan BinderCasper$4K
- Sherrill FoxCasper$4K
- Taylor PedersenCasper$4K
- Brehan NewellCasper$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.